Skip to main content
  • Jun 07, 2024

    The Path to Treatment Success With Extended Dosing Intervals of Next Generation Anti-VEGF Therapies for nAMD


    This case consult with Drs. Kaiser and Borkar presents a patient with newly diagnosed vision loss. After reviewing the diagnosis, the faculty discuss intravitreal anti-VEGF treatment options including the more durable therapies for neovascular age-related macular degeneration (nAMD). Approaches to selecting an agent and determining dosing intervals are demonstrated over 72 weeks of treatment. Discussion covers the patient’s response to her therapy and next steps based on visual and anatomic findings, and how to put into clinical practice the more durable anti-VEGF agents with longer dosing intervals.